Dublin, Jan. 20, 2017 -- Research and Markets has announced the addition of the "Advanced Drug Delivery Market Analysis & Trends - Technology, Route Of Administration, End User - Forecast to 2025" report to their offering.
The Global Advanced Drug Delivery Market is poised to grow at a CAGR of around 7.8% over the next decade to reach approximately $330.70 billion by 2025.
This industry report analyzes the global markets for Advanced Drug Delivery across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.
Some of the prominent trends that the market is witnessing include growing focus on unmet medical requirements, increasing demand for generic drugs and biosimilars, rising familiarities of chronic diseases and recent technological developments of advanced drug delivery.
Based on technology, the market is categorized into polymeric drug delivery, implants & IUD's, sustained release, targeted drug delivery and prodrugs. By polymeric drug delivery, the market is further divided into nebulizers, metered dose inhalers and dry powder inhalers.
Depending on the route of administration, the market is segmented into transdermal drug delivery system, oral, topical & injectable drug deliveries and transmucosal delivery systems.
By end user, the market is segregated into hospitals, diagnostic centers, ambulatory surgical centers/clinics, home care settings and other end users.
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Growing focus on Unmet Medical requirements
3.1.2 Increasing demand for Generic Drugs and Biosimilars
3.1.3 Rising familiarities of Chronic Diseases
3.1.4 Recent Technological Developments of Advanced Drug Delivery
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness
4 Advanced Drug Delivery Market, By Technology
4.1 Polymeric Drug Delivery
4.1.1.1 Nebulizers
4.1.1.2 Metered Dose Inhalers
4.1.1.3 Dry Powder Inhalers
4.2 Implants & IUD's
4.3 Sustained Release
4.4 Targeted Drug Delivery
4.5 Prodrugs
4.5.1 Prodrugs Market Forecast to 2025 (US$ MN)
5 Advanced Drug Delivery Market, By Route Of Administration
5.1 Transdermal Drug Delivery System
5.2 Oral, Topical & Injectable Drug Deliveries
5.3 Transmucosal Delivery Systems
6 Advanced Drug Delivery Market, By End User
6.1 Hospitals
6.2 Diagnostic Centers
6.3 Ambulatory Surgical Centers/Clinics
6.4 Home Care Settings
6.5 Other End Users
7 Advanced Drug Delivery Market, By Geography
8 Key Player Activities
8.1 Mergers & Acquisitions
8.2 Partnerships, Joint Venture's, Collaborations and Agreements
8.3 Product Launch & Expansions
8.4 Other Activities
9 Leading Companies
9.1 Merck & Co., Inc.
9.2 Antares Pharma, Inc.
9.3 F. Hoffmann-La Roche Ltd.
9.4 Novartis AG
9.5 Bayer AG
9.6 Sanofi
9.7 Glaxosmithkline PLC
9.8 3M Company
9.9 Pfizer, Inc.
9.10 Johnson & Johnson Services, Inc.
9.11 Abbott Laboratories
9.12 Allergan, Plc
9.13 Baxter International Inc.
9.14 Mylan Pharmaceutical company
9.15 Roche Holding AG
For more information about this report visit http://www.researchandmarkets.com/research/wqmqlm/advanced_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery


OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
First Western Ship Transits Strait of Hormuz Since Iran War Began
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 



